IGC Pharma Highlights AI-Driven Alzheimer's Drug Development Amid Federal Cannabis Schedule III Reclassification Momentum

IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy momentum surrounding the potential reclassification of cannabis to Schedule III and its implications for the regulated cannabinoid pharmaceutical sector.

Recent reports indicating a possible shift in federal scheduling have coincided with renewed market interest across the cannabinoid landscape, reflecting expectations that a clearer federal posture may reduce long-standing friction around research, manufacturing, and financial infrastructure. While such developments would not legalize cannabis or eliminate regulatory oversight, they underscore a broader transition toward recognizing clinically validated cannabinoid medicines as part of the mainstream pharmaceutical ecosystem.

IGC Pharma believes it occupies a distinct position at this inflection point: Unlike consumer-facing cannabis or hemp companies, IGC operates within the FDA-regulated drug-development pathway, with a focused strategy centered on neurological disorders and low-dose cannabinoid formulations designed for therapeutic effect with minimal psychoactivity. The Company's lead candidate, IGC-AD1, is currently being evaluated in a Phase 2 clinical trial for agitation associated with Alzheimer's disease (the CALMA study).